[Atopic eczema in childhood or primary immunodeficiency - what needs to be considered?]

about

[Atopic eczema in childhood or primary immunodeficiency - what needs to be considered?]

Item

http://www.wikidata.org/entity/Q49844868

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

[Atopic eczema in childhood or primary immunodeficiency - what needs to be considered?]

@en

[Atopic eczema in childhood or primary immunodeficiency - what needs to be considered?]

@nl

type

Item

label

[Atopic eczema in childhood or primary immunodeficiency - what needs to be considered?]

@en

[Atopic eczema in childhood or primary immunodeficiency - what needs to be considered?]

@nl

prefLabel

[Atopic eczema in childhood or primary immunodeficiency - what needs to be considered?]

@en

[Atopic eczema in childhood or primary immunodeficiency - what needs to be considered?]

@nl

P1476

[Atopic eczema in childhood or primary immunodeficiency - what needs to be considered?]

@en

P2093

Andreas Wollenberg

http://www.w3.org/2001/XMLSchema#string

Ellen Renner

http://www.w3.org/2001/XMLSchema#string

P2860

Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations

Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis

Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention

Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.

WASp in immune-system organization and function.

Comèl-Netherton syndrome defined as primary immunodeficiency.

Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis.

Guidelines for treatment of atopic eczema (atopic dermatitis) Part II.

Long term treatment concepts and proactive therapy for atopic eczema.

P2888

s15006-017-0330-y

P304

59-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S15006-017-0330-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

159

http://www.w3.org/2001/XMLSchema#string

P50

Beate Hagl

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092797414

http://www.w3.org/2001/XMLSchema#string

P698

29159616

http://www.w3.org/2001/XMLSchema#string